Amarin’s VAZKEPA Receives National Reimbursement in Greece, Expands European Market Presence with Exclusive Agreement with Vianex S.A.
In a substantial development for Amarin Corporation, the Greek Ministry of Health has granted national reimbursement for VAZKEPA (icosapent ethyl), a prescription fish oil derivative, to reduce cardiovascular risk in statin-treated adult patients with elevated triglycerides and other high-risk characteristics. This approval, based on the REDUCE-IT study, marks the seventh national reimbursement of VAZKEPA in Europe. Additionally, Amarin has entered into an exclusive marketing and commercialization agreement with Vianex S.A. a renowned Greek pharmaceutical company, further strengthening its foothold in the Greek market.
The Significance of National Reimbursement in Greece
The approval of VAZKEPA for national reimbursement in Greece is a significant milestone for Amarin. It allows eligible patients to have access to this innovative therapy, thereby improving treatment options for individuals with cardiovascular disease in the country. Given the high prevalence of cardiovascular risk factors and the subsequent burden of cardiovascular disease in Greece, the inclusion of VAZKEPA in the national reimbursement list is expected to have a profound impact on public health.
Efficacy of VAZKEPA as Studied in REDUCE-IT
The approval of VAZKEPA in Greece is based on the compelling findings from the landmark REDUCE-IT study. This randomized, double-blind, placebo-controlled trial involved over 8,000 patients with established cardiovascular disease or diabetes and other risk factors. The study demonstrated that VAZKEPA, when used as an adjunct to statin therapy, resulted in a 25% reduction in major adverse cardiovascular events, including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, and unstable angina hospitalizations. These remarkable results established VAZKEPA as a promising option for managing cardiovascular risk.
Expansion of VAZKEPA’s European Market Share
With the approval of national reimbursement in Greece, VAZKEPA continues to expand its market share in Europe. This achievement further bolsters Amarin’s position as a leading pharmaceutical company in the field of cardiovascular health. The increasing recognition and adoption of VAZKEPA across Europe testify to its potential in improving patient outcomes and reducing the burden of cardiovascular disease.
Exclusive Agreement with Vianex S.A.: A Strategic Partnership:
Amarin’s exclusive marketing and commercialization agreement with Vianex S.A. demonstrates the company’s commitment to advancing its cardiovascular portfolio and strengthening its presence in the Greek market. Vianex S.A. well-known for its excellence in pharmaceutical products and services, is the ideal partner for Amarin’s expansion plans. This strategic collaboration will enable Amarin to leverage Vianex S.A.’s extensive network, expertise, and market access to effectively promote VAZKEPA and ensure unparalleled patient access.
Conclusion:
The Greek Ministry of Health’s approval of VAZKEPA for national reimbursement is a laudable step in improving cardiovascular healthcare in Greece. By leveraging the results of the REDUCE-IT study, VAZKEPA has demonstrated its potential to significantly reduce major adverse cardiovascular events in high-risk patients. The exclusive agreement with Vianex S.A. further strengthens Amarin’s market position and creates a promising pathway for wider patient access to this groundbreaking therapy. As Amarin expands its presence in Europe, the prospects for improved cardiovascular outcomes and enhanced patient care are indeed promising.
Comments